LYEL — Lyell Immunopharma Share News
0.000.00%
Last trade - 00:00- $230.10m
- $26.00m
- $0.04m
U.S. STOCKS ON THE MOVE-Lennar, Jabil, Nvidia
U.S. STOCKS ON THE MOVE-Verve Therapeutics, Lyell Immunopharma, Energy companies
Lyell Immunopharma rises on promising data from blood cancer therapy study
Brief: Lyell Immunopharma Announces Positive Clinical Data From Phase 1/2 Trial Of Lyl314 For The Treatment Of Aggressive Large B-Cell Lymphoma
Brief: Lyell Immunopharma Strengthens Clinical And Commercial Capabilities With Key Board And Executive Appointments
Lyell Immunopharma Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Lyell Immunopharma Q1 Net Income USD -52.195 Million
Lyell Immunopharma Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: Lyell Immunopharma Inc - To Close West Hills Manufacturing Facility - SEC Filing
Brief: Lyell Immunopharma Q4 Net Income USD -191.935 Million
Brief: Lyell Immunopharma Says Impt-314 Receives Fast Track Designation From FDA
Brief: Lyell Immunopharma Files Prospectus Related To Resale From Time To Time By Selling Stockholders Of Up To 37.5 Million Shares Of Common Stock
Brief: Lyell Immunopharma Q3 Net Income USD -44.583 Million
Brief: Lyell Immunopharma To Acquire Immpact Bio And Prioritizes Its Pipeline To Focus On Next-Generation CAR T-cell Therapies
Brief: Lyell Immunopharma Q2 Net Income USD -45.809 Million
Brief: Lyell Immunopharma Reports Dose-Dependent Clinical Activity From Phase 1 Trial
Brief: Lyell Immunopharma Q1 Net Income USD -60.667 Million
Brief: Lyell Immunopharma Files For Mixed Shelf Of Up To $400 Mln
Brief: Cellares Says Co, Lyell To Evaluate Automated Manufacturing Of Lyell's Car T-Cell Therapy On Cellares' Cell Shuttle Platform